AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02061982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Description: Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
Study NCT02061982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee consumption
Description: Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
Study NCT01208818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO group
Description: TheraliteTM dialyzer of 2.1 m2 in surface
Study NCT02973217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Study NCT04073069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The DR group
Description: Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT04073069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The R group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT01725178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and Physical training
Description: Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management.
Study NCT03865056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow (High-flow Nasal Cannula)
Description: Optiflow will be applied for 20 minutes
Study NCT01208818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional high-flux dialyzer
Description: conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
Study NCT04341311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: - Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
Study NCT03865056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Ventilation
Description: non-invasive ventilation will be applied for 20 minutes
Study NCT05013593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Clover Extract (RCE)
Description: Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
Study NCT05013593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
Study NCT00887978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: treprostinil diolamine sustained release tablets
Study NCT00887978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02387866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Study NCT03394105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrapleural docetaxel administration
Description: intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
Study NCT00575107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
Study NCT00575107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard training of leg extension
Study NCT04341311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: - Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
Study NCT02840734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
Study NCT02840734 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
Study NCT02062970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood draw
Study NCT00549406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computerized visual training
Description: two one-hour training sessions per week, for five consecutive weeks
Study NCT00549406 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: computerized word puzzles
Description: two one-hour sessions per week, for five consecutive weeks
Study NCT00549406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-game based visual training
Description: two one-hour training sessions per week, for five consecutive weeks
Study NCT02335034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Group Educational courses, DVD, print material of lectures
Description: 2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
Study NCT02335034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group only make evaluations / consultations with all professional teams
Description: Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years.
Study NCT03766113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback coupling electroencephalogram and functional MRI in time actual
Description: One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
Study NCT03766113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording
Description: Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference.
Study NCT02597751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO-OP)
Description: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention.
Study NCT01691846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar+metformin
Description: 150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
Study NCT01691846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+metformin
Description: Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
Study NCT01690416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional palpation technique
Study NCT01690416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound DNTP
Study NCT00971724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, once daily, for 15 days
Study NCT00971724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration
Study NCT01340716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan exercise
Description: patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
Study NCT01340716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: patients in this group held weekly classes of two stretching for 12 weeks.
Study NCT01367236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: * atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*
Study NCT01367236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: novel treatment
Description: * darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily
Study NCT03481751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test: Ultrasound
Description: Transabdominal ultrasound of the bowel for categorization of disease activity
Study NCT04420767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
Study NCT04420767 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham brain stimulation
Description: Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
Study NCT04420767 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Go-No GO task
Description: During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
Study NCT04420767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go-No GO task
Description: During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
Study NCT03514836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVac/PCa
Description: Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy.
Study NCT03514836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: immunomodulatory medication given around the ONCOS-102 dosing
Study NCT01083316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4
Study NCT01083316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days
Study NCT01083316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1
Study NCT03304834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHOPULSE
Description: Patient are treated with the HIFU device and the physician is doing a compressive bandage.
Study NCT04131907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Description: The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
Study NCT04131907 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Optilume Sham Device
Description: 21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
Study NCT02187887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
Study NCT01645033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized Cognitive Behavioral Therapy (CBT)
Description: Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
Study NCT01645033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]
Study NCT01645033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]
Study NCT04308083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement
Description: Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
Study NCT04308083 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: dental implant placement
Description: Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
Study NCT03766113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording
Description: Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program
Study NCT02913833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain evaluation
Description: Pain will be assessed four times per day on a visual analogic scale.
Study NCT04534049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Strength Training (IST)
Study NCT04534049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Endurance Training (SET)
Study NCT00296049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Study NCT00296049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Study NCT02378077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy during scheduled abdominal surgery
Description: Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
Study NCT02378077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Aspiration
Description: Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
Study NCT02378077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement
Description: Fish Oil supplementation for three months.
Study NCT01204905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir and Maraviroc in combination
Description: Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart
Study NCT00268944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow
Study NCT00100568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily
Study NCT00100568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: 150mg lamivudine/300mg zidovudine tablet taken orally twice daily
Study NCT04196855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone.
Study NCT00824252 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires & Study Visit
Description: Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
Study NCT01715688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkalinized lidocaine
Description: Administration of alkalinized lidocaine in the endotracheal tube cuff
Study NCT01715688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline in the endotracheal tube cuff
Study NCT02314156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Given transdermally
Study NCT03064451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cartofinder guided ablation followed by PVI
Description: cartofinder guided ablation followed by PVI